|Articles|December 16, 2016
Commonwealth Signs Agreement with FDA
Commonwealth Informatics has signed a new contract to support the use of advanced drugs safety tools at the FDA Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.
Advertisement
Commonwealth Informatics has signed a new contract to support the use of advanced drugs safety tools at the FDA Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research. This contract was a follow-up to an FDA Agreement announced in June , which includes:
- A one year commitment of ~$900K for support and consulting and four additional option years with an increasing amount each year.
- Support for one of the largest implementations of
Oracle Empirica Signal as with up to 300 users accessing the suite to track the safety of marketed drugs and those in the approval process - recent batch of new drug approvals requires more safety review.
- The contract provides support for the
FDA’s 21st Century regulatory review process initiative.
Read the full release here
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Ensuring Digital Trial Platforms Work for Underserved Communities
September 10th 2025
- eClinical Technology: Misconceptions, Challenges, and Opportunities
September 9th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational OX40-Targetting T-Cell Therapy Shows Durable Efficacy Treating Atopic Dermatitis in Phase III Trial
2
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
3
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
4
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
5